New Medicine Development: Big Investors


Biopharma companies are crabbing up their drug research & development spending after staying stable all the way through last couple of years. According to industry sources, research & development investments will top $136 billion in 2013, up from $ 134 billion (2012); also the R&D expenditures estimated to exceed ($ 149 billion) by 2017.

Drug Development Costs: Average cost to develop a drug
  • Early 2000s = $1.2 billion approx
  • Late 1990s = $800 million
  • Mid 1980s = $320 million
  • 1970s = $140 million
New medicine development – Big investors:
  • According to recent industry surveys: NovoNordisk will have the fastest growth in Research & Development spending, from $1.8 billion in 2011 to $3.1 billion in 2018, an 8 % increase in investments.
  • Novartis is predicted to spend on R&D the most $10.1 billion – by 2018.
  • Roche is expected to spend $8.7 billion.
  • Merck & Co., is expected to spend $7.6 billion.
  • GlaxoSmithKline, is expected to spend $7.2 billion
  • Pfizer, is expected to spend $6.7 billion
  • Sanofi, is expected to spend $6.7 billion
  • Johnson & Johnson, is expected to spend $5.9 billion
  • Eli Lily, is expected to spend $4.7 billion
  • Bristol-Meyers Squib, is expected to spend $4.2 billion
  • AstraZeneca is expected to spend $4.1 billion: according to the sources several major biopharma companies are expected to spend less on R&D over the next 6 years (including Pfizer, Merck & Co, AstraZeneca and Eli Lilly.)

Click here to Continue Reading
For more updates visit Harneedi.com 

Comments

Popular posts from this blog

This Summer beware of the Heat Stroke… It could be Fatal

Safeguard Measures to tackle the menace of Monsoon-related diseases

Apoptosis Signaling Pathway